01.12.2015 - Almirall is strengthening its dermatology focus with the takeover of Poli Group. Part of the deal are the group’s two pharma companies, German Taurus Pharma GmbH and Swiss Polichem S.A., and Italian Polichem S.r.l., which produces plastics additives.
Barcelona-based Almirall S.A. is paying at least US$385m (€364m) for 100% of the share capital of Poli Group Holding S.r.l. With this transaction, Almirall aims to become a top global player in dermatology. The deal will net the company a dermatology-focused R&D structure and a significant growth in revenues.
Poli Group brings its proprietary formulation technology (HPCH) and three clinical stage pipeline projects into the deal. The group also has several products already on the market, most notably Ciclopoli, the flagship product for the treatment of nail diseases (onychomycosis), but also Sililevo, used to treat nail psoriasis, and Zeloglin for the treatment of rosacea.
Jorge Gallardo, President of Almirall, commented: “This important transaction is the result of our continued focus on growing our presence in the global Dermatology market. The products of Poli Group will provide Almirall with leading market positions in key geographies in which we want to increase our footprint. We still have room to grow in dermatology and will continue to analyse opportunities in the market.” The company plans to finalise the takeover within the next few months.
26.11.2015 Bioeconomy movers and shakers from every corner of the globe met this week at the world’s first Global Bioeconomy Summit in Berlin to discuss, debate and define better ways to ensure the bioeconomy succeeds on an international level.
24.11.2015 After weeks of speculation it is official: US pharma major Pfizer and Irish Botox maker Allergan will merge. With the deal, Pfizer is planning to dodge the high US taxes, causing indignation among US politicians.
23.11.2015 Amidst talk of the IPO window closing and cancelled flotations, diagnostics firms are still striking a chord with investors. Swedish Immunovia and German Curetis are successfully raising public money.
17.11.2015 The first Italian accelerator specifically for biotech projects has been launched with help from Sofinnova Partners. The plan of BiovelocITA: to help Italy grow into one of Europe’s strongest biotech markets.
13.11.2015 Scientists in Bath, UK, have developed a medical dressing that turns fluorescent green when it detects infection. The researchers hope that the smart burns dressing will help fight antibiotic resistance.
13.11.2015 Out with the old: Roche is discarding four sites with 1,200 staff in an effort to restructure its manufacturing network for small molecules. Instead, a new manufacturing site will be built in Switzerland.
10.11.2015 Algae have many skills, but cancer fighting was not one of them – until now. Researchers from Australia and Germany have genetically engineered diatom algae to accurately deliver chemotherapeutic drugs.